Ondas Holdings: The Clash Between a $150 Million Order Surge and a 40% Insider Exit

Ondas Holdings presents a study in contradictions. Its defense business is booming – second-quarter order intake topped $150 million – while its stock has tumbled 35.6% in the past month. The tension between operational momentum and market skepticism is embodied by two opposing forces: a CEO who just sold nearly 40% of his personal stake and institutional investors who are piling in.

Chief executive Eric Brock unloaded 2.38 million shares in June, a transaction valued at roughly $32.1 million that reduced his holdings by 39.9%. The move might look like a red flag, but the company has explained that the sale was purely to cover tax obligations stemming from exercised stock options – not a discretionary bet against the equity. Over the preceding 90 days, insiders as a group sold 2.4 million shares worth about $32.1 million, and director Seidl had shed 10,000 shares in May.

Yet while company executives trimmed their positions, deep-pocketed institutions were doing the opposite. Vanguard boosted its stake by 39.9%, ending the period with 18.8 million shares. State Street raised its position by a striking 130.2%, and Two Sigma increased its holding by a jaw-dropping 1,325.9%. The divergence raises an obvious question: are the insiders signaling something the big money is missing, or is the sell-off simply an overreaction to a tax-driven liquidity event?

Defense deals pile up

The operational story remains compelling. In June alone, Ondas secured more than $40 million in new orders from governments and militaries around the world, largely for counter-drone systems. That helped push total second-quarter bookings past $150 million. The subsidiary Sentrycs also achieved a strategic milestone by integrating its cyber-radio technology into a Lockheed Martin defense platform. An additional feather in the cap came from a successful test flight of the SkyLance system for the UK Ministry of Defence.

On the financial front, the first quarter delivered a mixed bag. Revenue surged roughly tenfold year-on-year to about $50 million, and the company reported a headline net profit of nearly $362 million. But the core business remains a cash burner: the operating loss stood at $43 million, and free cash flow sank deeper into negative territory. The rapid growth is consuming enormous financial resources.

Should investors sell immediately? Or is it worth buying Ondas Holdings?

Adding to the pressure on the stock is an overhang of more than 9 million existing shares that could come to market. Ondas has filed documents for a potential sale of these shares, which originated from previous acquisitions. The offering would bring no new cash into the company but would increase the supply of tradable shares, acting as a near-term brake on the share price.

Technical and analyst signals

Chart-wise, the stock is approaching oversold territory. The 14-day relative strength index sits at 34.1, and the current price of €6.91 – up about 7% on Friday after closing at €6.45 the previous day – remains 22.85% below the 50-day moving average of €8.36 and 17.37% below the 200-day average of €7.81. From the January peak of €13.02, the stock has fallen 50.46%.

Analysts, however, remain broadly bullish. Of the eight ratings on the stock, six are “Buy” and one is “Strong Buy,” with only one “Hold” and one “Sell.” The average price target stands at $17.25, implying significant upside from current levels. The stock is also up 303.12% over the trailing twelve months, underscoring the violent swings that have become its hallmark.

That volatility – annualized at roughly 107% – is the thread that ties the whole narrative together. A defense-driven growth story is colliding with a share overhang and insider selling, creating a tug-of-war that has already produced a 52-week range from €1.50 to €13.02. For Ondas, the market’s attention is split between the order book and the supply of paper, and only when the overhang is absorbed is the fundamental growth story likely to regain center stage.